electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
BASKING RIDGE, N.J.,
|
"We are pleased to have three distinguished members join our Board of Directors in conjunction with our recently completed initial public offering, each of whose impressive pharmaceutical and business experience is invaluable to the company’s continued growth and expansion," said Frank Amato, Chief Executive Officer, electroCore. “Further, we look forward to having Ms. Cox lend her extensive leadership experience and depth of expertise with companies in electroCore’s stage of commercialization as Chairman.”
Ms. Cox brings three decades of experience in the pharmaceutical industry to her role as Chairman. Ms. Cox most recently served as Chief Executive Officer of
Mr. Atieh spent the majority of his career in the biotechnology and pharmaceutical industries, including 20 years at
Dr. Ondra is Chief Executive Officer of
Commenting on her Chairman appointment, Ms. Cox said, “I am honored to be joining the electroCore Board of Directors during a pivotal time in the company’s history. I look forward to working with my fellow directors and becoming a part of the electroCore team, furthering a commitment to shifting the treatment paradigm and providing patients with a safer solution for managing pain.”
These Board appointments complement several recent milestones for electroCore. In conjunction with its initial public offering, the company's common stock began trading on the Nasdaq Global Market under the symbol ECOR on
electroCore’s Board of Directors consists of senior executives from the business, pharmaceutical, medical devices and medicine sectors. Members of the Board include: Frank Amato, Chief Executive Officer of electroCore; J.P. Errico, Chief Science & Strategy Officer of electroCore; Thomas J. Errico, M.D., Professor of Orthopedic and Neurological Surgery,
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.
Contacts
Investors:
Greg Chodaczek or Lynn Lewis
Gilmartin Group
investors@electrocorellc.com
(646) 924-1769
or
Media:
Alexandra Canale
(617) 921-9353
alexandra.canale@gcihealth.com
Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/7ca8e0d4-d2a7-445b-86f0-97cf81969605
http://www.globenewswire.com/NewsRoom/AttachmentNg/07f58ec9-4214-48ef-a62e-173d3f9af09e
http://www.globenewswire.com/NewsRoom/AttachmentNg/1acdb5a5-862d-4077-8383-ce1bacdec3f5